Vimarsana
Biggest News Aggregation in the World

Page 10 - Iontech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Iontech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Iontech Today - Breaking & Trending Today

Pfizer and BioNTech seek to cancel Moderna patents at PTAB - Vimarsana News

Pfizer and BioNTech seek to cancel Moderna patents at PTAB

Latest round in Covid-19 mRNA vaccine patent litigation battle

A snapshot of cancer vaccine development - Vimarsana News

A snapshot of cancer vaccine development

At a pivotal moment in cancer vaccine research, the MIT Koch Institute Annual Symposium explored emerging successes and obstacles in the field in areas that include immunology, next-generation tools and models, and mRNA and other vaccine platforms.

Source: mit.edu
Acuitas Seeks Declaratory Judgment Of Non-Infringement And Invalidity Against Arbutus And Genevant In New Jersey Court Challenging MRNA-Delivery Specific Patents - Patent - Vimarsana News

Acuitas Seeks Declaratory Judgment Of Non-Infringement And Invalidity Against Arbutus And Genevant In New Jersey Court Challenging MRNA-Delivery Specific Patents - Patent

Last week, Canada-based Acuitas Therapeutics, Inc. (Acuitas) filed a complaint in the District of New Jersey for declaratory judgment of non-infringement and invalidity against Arbutus Biopharma Corp...

Source: mondaq.com
BioNTech SE (NASDAQ:BNTX) Q2 2023 Earnings Call Transcript - Vimarsana News

BioNTech SE (NASDAQ:BNTX) Q2 2023 Earnings Call Transcript

BioNTech SE (NASDAQ:BNTX) Q2 2023 Earnings Call Transcript August 7, 2023 Operator: Welcome to BioNTech’s Second Quarter 2023 Update Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations. Please go ahead. Victoria Meissner: Thank you. Good morning and afternoon. Thank you for joining us […]

Source: yahoo.com
BioNTech reduces drug development spend as COVID vaccine sales plunge - Vimarsana News

BioNTech reduces drug development spend as COVID vaccine sales plunge

FRANKFURT (Reuters) -Germany's BioNTech, Pfizer's partner on COVID-19 vaccines, cut its drug development budget for this year after quarterly revenues were hurt by a plunge in pandemic-related demand. Second-quarter revenue dropped to 167.7 million euros ($184 million) from 3.2 billion euros a year earlier, as write-offs on Pfizer's assets ate into profit share payments that BioNTech is entitled to receive from its U.S. partner. "With some uncertainty on the revenue line, we are also carefully watching our spending by revisiting our cost base," said finance chief Jen...

Source: yahoo.com